China's scientific and technological innovation brings benefits to the treatment of major diseases
Xinhua News Agency, Beijing, January 15 (Reporter Wang Kun) "The world's first anti-AIDS long-acting fusion inhibitor was approved for marketing" "original anti-Alzheimer's disease new drug entered the market application" "first implantable artificial heart clinical Successful trials have treated 9 patients with end-stage heart failure."... The reporter learned from the Ministry of Science and Technology that in 2018, China's new drug creation achieved a major breakthrough, and science and technology improved people's livelihood and prosperity.
According to the relevant person in charge of the Ministry of Science and Technology, China successfully carried out the first international clinical study of full-length pulp regeneration, and the domestic positron emission tomography/magnetic resonance imager (PET/MR) was approved for marketing. The National Clinical Medical Research Center has developed a number of medical treatment guidelines and technical specifications to effectively support the level of diagnosis and treatment and service capacity.
In 2019, the Ministry of Science and Technology will strengthen major products such as new drugs and high-end medical devices, and launch major projects on prevention and treatment of major diseases such as cancer, cardiovascular and metabolic diseases. Improve the layout of national clinical medical research centers and organize large-scale, multi-center clinical research. At the same time, strict review of human genetic resources management and high-level pathogenic microbiology laboratory construction review.